An interventional study of Alma system in Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\) and PPH, sponsored by ResQ Medical Ltd. Recruiting at 1 site in Kenya. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by ResQ Medical Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Postpartum Hemorrhage (PPH) is an obstetric emergency that can occur up to 24 hours after vaginal birth or cesarean section.
In most cases, the uncontrolled bleeding is due to a lack of sufficient contraction of the uterus (hypotonia) and appears immediately after birth.
The purpose of this prospective, non-randomized, feasibility pilot study is to obtain information on the safety and effectiveness of an investigational new medical device - Alma System, that is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.
A prospective, non-randomized, feasibility pilot study that is intended to obtain information on the safety and effectiveness of the Alma System.
Study population: Women with vaginal deliveries in a hospital setting who failed first-line therapies for postpartum hemorrhage.
The main questions are:
Main tasks for participants:
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
This study's planned enrollment of 10 is below the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Browse Postpartum Hemorrhage studies →ResQ Medical Ltd is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PPH that the investigator determines to require more aggressive treatment, including any of the following:
Placental abnormality including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group which Alma treatment was applied
Device: Alma system
Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
Also known as: Vacuum induced heamorrhage control, Obstetric-gynecologic specialized manual instrument
Rate of Related SAEs
Rate of device related SAEs up to six weeks following device treatment.
Time frame: 6 weeks
Rate of Damage to Cervix, Uterus or Vagina
Rate of any observable damage to cervix, uterus or vagina during or immediately after device procedure
Time frame: When removing the Alma System at the end of the procedure
Rate of Occurrence of Uterine Inversion or Folding
Rate of occurrence of uterine inversion or folding during or immediately after device procedure
Time frame: When removing the Alma System at the end of the procedure
User Feedback on Placement of Alma
Rate of positive user feedback on device placement trans-vaginally
Time frame: When removing the Alma System at the end of the procedure
User Feedback on Connection to Vacuum
Rate of positive user feedback on connection to vacuum and maintenance of desired negative pressure
Time frame: When removing the Alma System at the end of the procedure
Rate of Uterine Contraction
Rate of uterine contraction to a level that reduces or stops blood flow
Time frame: When removing the Alma System at the end of the procedure
Time to Visible Reduction in Blood Flow
Time from insertion and start of negative pressure to visible reduction in blood flow
Time frame: When removing the Alma System at the end of the procedure
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2024 (actual). Primary completion is estimated for Jun 2025, 9 months after the start.
Of 112 non-industry interventional studies with no phase under Postpartum Hemorrhage, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 9 months is below that.
Counting every sponsor, half of 119 studies reached it within 16 months; a quarter within 7 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.